PTPN12 and cancer: Furthermore, in cancers with loss of a common negative feedback inhibitor of RTK activation such as loss of PTPN12 expression, single-agent RTK inhibition is ineffective because of hyperactivation of multiple RTKs (Sun et al., 2011).